Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma

Yuan, Zuyang; Gao, Shugeng; Mu, Jianjun; Xue, Qi; Mao, Yousheng; Wang, Dali; Zhao, Jun; Gao, Yushun; Huang, Jinfeng; He, Jie

doi:10.21037/jtd.2016.08.56

Cited by 10 publications

(21 citation statements)

References 46 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we also tried to find biomarkers that could be used as prognostic factors for TC. The serum level of lactic dehydrogenase has been reported to be a prognostic factor for TC [13,20,21]. Our study found that the serum level of lactic dehydrogenase affected the postoperative recurrence of TC.…”

Section: Commentsupporting

confidence: 56%

A Nomogram Predicting Recurrence and Guiding Adjuvant Radiation for Thymic Carcinoma After Resection

Wang

et al. 2018

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

show abstract

Section: Commentsupporting

confidence: 56%

A Nomogram Predicting Recurrence and Guiding Adjuvant Radiation for Thymic Carcinoma After Resection

Wang

et al. 2018

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…Pretreatment serum LDH level along with TNM staging might more accurately predict disease risk definition and can serve as an independent, robust, reliable biomarker for predicting overall survival (OS), disease-free survival (DFS) as well as distant metastasis-free survival (DMFS) [107]. Serum LDH is also an independent predictor of decreased progression-free survival (PFS) in thymic carcinoma patients [108] as well as in high-grade osteosarcoma patients where it has been found to be a strong predictor of skeletal metastasis [109]. Hepatocellular carcinoma (HCC), patients with higher preoperative serum LDH levels have a worse prognosis following hepatectomy for both OS and DFS [110]; Ewing′s sarcoma patients with similarly high levels of preoperative serum LDH showed lower OS and 5-year DFS rates [111].…”

Section: Serum Ldh Profile In Cancers and Clinical Relevancementioning

confidence: 99%

Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment

Mishra

Banerjee

2019

Cancers

177

130

View full text Add to dashboard Cite

Cancer is a metabolic disease in which abnormally proliferating cancer cells rewire metabolic pathways in the tumor microenvironment (TME). Molecular reprogramming in the TME helps cancer cells to fulfill elevated metabolic demands for bioenergetics and cellular biosynthesis. One of the ways through which cancer cell achieve this is by regulating the expression of metabolic enzymes. Lactate dehydrogenase (LDH) is the primary metabolic enzyme that converts pyruvate to lactate and vice versa. LDH also plays a significant role in regulating nutrient exchange between tumor and stroma. Thus, targeting human lactate dehydrogenase for treating advanced carcinomas may be of benefit. LDHA and LDHB, two isoenzymes of LDH, participate in tumor stroma metabolic interaction and exchange of metabolic fuel and thus could serve as potential anticancer drug targets. This article reviews recent research discussing the roles of lactate dehydrogenase in cancer metabolism. As molecular regulation of LDHA and LDHB in different cancer remains obscure, we also review signaling pathways regulating LDHA and LDHB expression. We highlight on the role of small molecule inhibitors in targeting LDH activity and we emphasize the development of safer and more effective LDH inhibitors. We trust that this review will also generate interest in designing combination therapies based on LDH inhibition, with LDHA being targeted in tumors and LDHB in stromal cells for better treatment outcome.

show abstract

“…With regard to thymic malignancies, Yuan et al demonstrated that high serum LDH (>225 IU/L) was an independent predictor of decreased PFS in 95 patients with thymic carcinoma. It was also found that high LDH was significantly associated with advanced Masaoka stage 13 . Similarly, Liu et al found that baseline serum LDH level was independently associated with OS and disease‐free survival after thymic carcinoma resection.…”

Section: Discussionmentioning

confidence: 91%

Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP‐LATimus)

et al. 2021

View full text Add to dashboard Cite

Background Thymomas are a group of rare neoplasms of the anterior mediastinum. The objective of this study was to describe the demographics, clinical characteristics and treatment approaches in Latin America. Methods This was a retrospective multicenter cohort study including patients with histologically proven thymomas diagnosed between 1997 and 2018. Demographics, clinicopathological characteristics and therapeutic outcomes were collected locally and analyzed in a centralized manner. Results A total of 135 patients were included. Median age at diagnosis was 53 years old (19–84), 53.3% (n = 72) of patients were female and 87.4% had an ECOG performance score ranging from 0–1. A total of 47 patients (34.8%) had metastatic disease at diagnosis. Concurrent myasthenia gravis occurred in 21.5% of patients. Surgery was performed in 74 patients (54.8%), comprising 27 (20%) tumorectomies and 47 (34.8%) thymectomies. According to the Masaoka‐Koga system, overall survival (OS) at five‐years was 73.4%, 63.8% and 51%, at stages I–II, III–IVA and IVB, respectively (p = 0.005). Furthermore, patients with low lactate dehydrogenase (LDH) (≤373 IU/L) at baseline and myasthenia gravis concurrence showed significantly better OS (p = 0.001 and p = 0.008, respectively). In multivariate analysis, high LDH levels (HR 2.8 [95% confidence interval [CI]: 1.1–7.8]; p = 0.036) at baseline and not performing a surgical resection (HR 4.1 [95% CI: 1.3–12.7]; p = 0.016) were significantly associated with increased risk of death. Conclusions Our data provides the largest insight into the clinical characteristics and outcomes of patients with thymomas in Latin America. Survival in patients with thymomas continues to be very favorable, especially when subjected to adequate local control.

show abstract

Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma

Abstract: High serum LDH (>225 U/L) was an independent predictor of decreased PFS in thymic carcinoma patients. It was also significantly associated with reduced OS, but was not an independent predictor of death in those patients.

Cited by 10 publications

References 46 publications

A Nomogram Predicting Recurrence and Guiding Adjuvant Radiation for Thymic Carcinoma After Resection

A Nomogram Predicting Recurrence and Guiding Adjuvant Radiation for Thymic Carcinoma After Resection

Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment

Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP‐LATimus)

Contact Info

Product

Resources

About